908 organization(s) found
EHA
The European Hematology Association (EHA) is the largest hematology community in Europe. A not-for-profit, membership-driven association based in the Netherlands. Effectively advocating for our members and the wider community at the highest level. Organizer of the annual EHA Congress, Europe’s largest hematology event.
EHESP (Ecole des hautes études en santé publique)
The EHESP is a public establishment with a dual role of education and research into public health and social welfare. It encourages synergy between the disparate cultures of public health and management. Four missions are conferred to EHESP by law: · to provide training for persons who have to exercise leadership, management, inspection or control functions in the health, social or medico-social fields; · to provide a network of higher education in public health; · to contribute to public health research activities; · to develop international relations, in particular through exchanges with institutions providing comparable teaching. The EHESP stands for the values of defending fundamental collective values around public service ethics, general interest, respect, openness and cooperation, continual improvement, and social and environmental responsibility.
Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to inventing and developing breakthrough therapeutics through the purposeful integration of science and engineering.
EKCC - Addis Ababa (Else Kröner Center for Cancer Care)
The Else Kröner Center for Cancer Care (EKCC) project in Ethiopia is a comprehensive initiative aimed at enhancing and decentralizing cancer care in the country to reduce morbidity and mortality rates associated with breast and cervical cancer. With a budget of 2.5 million euros, the project lasts from February 2020 to January 2026. The project is being implemented by the Addis Ababa University School of Public Health in collaboration with the medical Faculty of Medicine at Martin Luther University Halle-Wittenberg.
Ellipses Pharma
Ellipses Pharma develops new treatments for cancer that address unmet clinical need. We are focused exclusively on the development of innovative cancer medicines.
ELLyE (Ensemble Leucémie Lymphomes Espoir)
French association of patients and relatives affected by lymphoma, chronic lymphocytic leukemia or Waldenström disease. Formerly France Lymphome Espoir.
Elpiscience Biopharmaceuticals
Elpiscience has pioneered a globally leading pipeline of groundbreaking immunotherapies, focusing on critical targets to address the significant unmet clinical needs in oncology and autoimmune diseases.
EMA (European Medicines Agency)
European Union agency in charge of the evaluation and supervision of medicines.
EORTC (European Organisation for Research and Treatment of Cancer)
Independent organisation that designs and runs academic cancer clinical trials across Europe.
Epigenic Therapeutics
Dedicated to developing next-generation gene modulation therapy utilizing regulation of the epigenetic genome for a variety of human diseases
Epitopea
We believe better cancer therapies are needed to transform people's lives. We are developing accessible off-the-shelf cancer RNA immunotherapies that will deliver durable benefits.
ERIC (European Research Initiative on CLL)
European network of researchers and clinicians working on chronic lymphocytic leukemia.
ErVimmune
ErVimmune develops cancer vaccines and T cell-based therapies as breakthrough immunotherapies to address unmet medical needs in cold tumors. We are dedicated to discovering more accurate non-mutated tumor epitopes that are shared across patients and indications. Supported by a proprietary, AI-driven target discovery platform, we focus on non-conventional antigens derived from human endogenous retroviruses (HERVs) as targets that we validate by proteomics and immunology assays. From bioinformatics to proteomics!
ESH
The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology.
ESID (European Society for Immunodeficiencies)
The European Society for immunodeficiencies (ESID) is a non for profit association that was created in 1994. ESID has been striving to improve the knowledge in the field of Primary Immunodeficiency (PID) by encouraging research, developing educational programs and fostering cooperation among all those involved in the diagnosis, treatment and management of these diseases. ESID is organized in 7 working parties – Inborn Errors, Clinical, Education, Genetics, Registry, ESID Juniors, PID Care in Development. ESID has invested in several activities such as: · ESID Biennial Congress; · ESID Summer School; · Endorsed activities; · Awards and Grants; · ESID Registry; and · ESID Guidelines
ESMO
The European Society for Medical Oncology's (ESMO) core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate – doctors, cancer patients and the general public – on the best practices and latest advances in oncology. And it is to promote equal access to optimal cancer care for all patients.
ESO
The European School of Oncology (ESO) is an independently funded non profit organisation dedicated to quality education and training, because we believe all patients deserve equal access to competent cancer care.
Esperantra
In Spanish: "ESPERANTRA es una organización sin fines de lucro, fundada con el propósito de contribuir en la reducción de la mortalidad por cáncer, enfermedades raras y crónicas no transmisbles en el Perú y mejorar la calidad de vida de los pacientes, abogando por la igualdad de acceso a tratamientos de calidad y cuidados innovadores. Hasta el 2005 no existía ninguna organización que representara y catalizara las necesidades de los pacientes, por tal motivo se creo ESPERANTRA. Somos la primera organización a nivel nacional que proporciona información y ayuda a través de sus diversos programas orientados al bienestar de los pacientes de todas las edades y sus familiares. MISIÓN: Informar, educar y orientar a los pacientes, familiares y población en general para lograr un diagnostico oportuno mediante programas de prevención responsable y control de la enfermedad trabajando en conjunto con los tomadores de desiciones para mejorar la calidad de vida de los pacientes del Perú con estos diagnósticos."
ESPUM (École de santé publique)
The only French-language school in the world and the second in Canada to be accredited by the Council on Education for Public Health (CEPH), the School of Public Health of the Université de Montréal (ESPUM) is a centre of excellence and critical thinking in teaching, research and knowledge translation in all fields of public health. Drawing on knowledge derived from scientific excellence, the School offers recognized high-level training for undergraduate and graduate students.
ESTRO (European Society for Radiotherapy & Oncology)
ESTRO’s new vision statement for 2030 ‘Radiation Oncology. Optimal Health for All, Together.’ emphasizes the ambition of the Society to further reinforce radiation oncology as core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. To do so, it will actively focus on translating science and evidence into practice. It will continue to support all radiotherapy professionals in their needs of continuous professional development. The needs of a growing Society in terms of governance and leadership will actively be addressed. The Society will also increasingly embrace its role in policy, through a broadening network of partnerships with all relevant stakeholders. Without calling for a disruptive change with the past, but conscious of the challenges ahead, the ESTRO vision statement for 2030 is ambitious, expansive, inclusive and open to the future.
EURACAN
EURACAN is a consortium of 102 European expert centres, European Patients Advocates (ePAGs) and relevant stakeholders whose goal is to improve access to care and clinical excellence for patients with Rare Adult Solid Cancers (RASCs) across the European Union and Ukraine.